Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02009332 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
A Phase 1 study, sponsored by Aadi Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02009332 is a Phase 1 study that has completed, run by Aadi Bioscience. The registered enrollment target is 21 participants.
The verdict
NCT02009332, a Phase 1 study, has completed, sponsored by Aadi Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Purpose of this study is to determine appropriate dosing of ABI-009 and evaluate the safety and anti-tumor activity of ABI-009 in treatment of non-muscle invasive bladder cancer
Interventions
- DRUG Gemcitabine
- DRUG ABI-009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-04-09 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02009332
The ClinicalTrials.gov registry entry for NCT02009332 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aadi Bioscience, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT02009332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02009332 about?
NCT02009332 is a clinical study titled "Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer". Purpose of this study is to determine appropriate dosing of ABI-009 and evaluate the safety and anti-tumor activity of ABI-009 in treatment of non-muscle invasive bladder cancer
What is the current status of trial NCT02009332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2014-04-09. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT02009332?
The interventions under investigation include: Gemcitabine (DRUG), ABI-009 (DRUG).
Who is sponsoring clinical trial NCT02009332?
This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.